Category Archives: Patent

Trump’s Executive Order on Drug Prices Might Be More in Favour of Drug Companies

The order will likely be a far cry from the president’s previous remarks about the pharmaceutical industry. Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six-page document outlining the draft provisions or objectives of a proposed presidential executive … Continue reading

Posted in Drug prices, Patent, Patent Term Extension, Uncategorized | Leave a comment

 The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?

 Lawmakers are concerned that giving a drug company a monopoly on the promising vaccine could make it unaffordable. 

Posted in Drug prices, Patent, R&D, Uncategorized | Leave a comment

US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices

By Frederick M Abbott*, IP Watch | 31/05/2017 The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. … Continue reading

Posted in Cancer, Patent, R&D, Uncategorized | Leave a comment

MSF criticizes Swiss pharma aims at upcoming India-EFTA trade talks

Source: Pharma Letter On May 30, 2017 (tomorrow), trade talks will resume for the India-EFTA (European Free Trade Association) free trade agreement (FTA) in Liechtenstein, between India and the EFTA countries of Switzerland, Norway, Iceland and Liechtenstein. Through this deal, … Continue reading

Posted in EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment

Pharmaceuticals & Patents, a talk by Justice Prabha Sridevan

  I am grateful to the Dr. N.S. Gopalakrishnan for inviting me to inaugurate this workshop, the theme being “Pharmaceuticals and patents.” This is a very important one today when there is a claim for a strong patent regime. But I must … Continue reading

Posted in Patent, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Intellectual property, affordable medicine, and universal health care

By Dr. Maria Guevara, Business world online| May 05, 2017 MANILA IS SET to host the 18th round of the multilateral trade deal — the Regional Comprehensive Economic Partnership (RCEP) that encompasses 50% of the global population.  With the Philippines … Continue reading

Posted in IPR, Patent, Patents, Regional Comprehensive Economic Partnership, TPP, TRIPS, Uncategorized | Leave a comment

MSF response on RCEP negotiations in the Philippines

Source: MSF Access Campaign New Delhi, 8 May 2017 – The Philippines is set to host the 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement’s negotiations in Manila this week. Negotiators from the ten members of the … Continue reading

Posted in Data Exclusivity, Evergreening, Investor state dispute, IPR Enforcement, ISDS, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized, WTO | Leave a comment